George M. Haig

Suggest Changes
Learn More
OBJECTIVE The authors sought to evaluate the efficacy and safety of ABT-126, a selective α7 nicotinic receptor partial agonist, in stable patients with schizophrenia. METHOD A 12-week,(More)